AQR Capital Management
NAGE

AQR Capital Management’s Niagen Bioscience NAGE Stock Holding History

AQR Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51M Sell
472,056
-559,279
-54% -$2.27M ﹤0.01% 2791
2026
Q1 		$4.55M Buy
1,031,335
+425,381
+70% +$2.3M ﹤0.01% 1809
2025
Q4 		$3.85M Buy
605,954
+18,957
+3% +$132K ﹤0.01% 1738
2025
Q3 		$5.48M Buy
586,997
+95,386
+19% +$963K ﹤0.01% 1403
2025
Q2 		$7.08M Buy
491,611
+139,475
+40% +$1.38M 0.01% 1106
2025
Q1 		$2.43M Buy
352,136
+329,425
+1,451% +$2.07M ﹤0.01% 1504
2024
Q4 		$120K Buy
22,711
+3,075
+16% +$16.8K ﹤0.01% 2746
2024
Q3 		$71.7K Buy
+19,636
New +$61.8K ﹤0.01% 2684
2022
Q4 		– Sell
-76,571
Closed -$94K – 2297
2022
Q3 		$94K Sell
76,571
-156,232
-67% -$251K ﹤0.01% 2111
2022
Q2 		$389K Sell
232,803
-180,986
-44% -$354K ﹤0.01% 1766
2022
Q1 		$1.02M Buy
413,789
+181,358
+78% +$496K ﹤0.01% 1523
2021
Q4 		$869K Buy
232,431
+60,590
+35% +$327K ﹤0.01% 1617
2021
Q3 		$1.08M Buy
171,841
+55,854
+48% +$460K ﹤0.01% 1496
2021
Q2 		$1.14M Buy
115,987
+38,650
+50% +$337K ﹤0.01% 1524
2021
Q1 		$722K Sell
77,337
-81,559
-51% -$646K ﹤0.01% 1691
2020
Q4 		$763K Buy
158,896
+17,695
+13% +$86.3K ﹤0.01% 1616
2020
Q3 		$566K Buy
+141,201
New +$681K ﹤0.01% 1667
2019
Q4 		– Sell
-23,024
Closed -$91K – 2192
2019
Q3 		$91K Buy
+23,024
New +$98.2K ﹤0.01% 2085

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management's NAGE Position: Q2 2026 in Review

AQR Capital Management reduced its Niagen Bioscience (NAGE) stake by 54% in Q2 2026, selling an estimated $2.27M and leaving 472,056 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2791.

AQR Capital Management first reported a position in NAGE in Q3 2019 and has held it in 18 quarters since. The position peaked at $7.08M in Q2 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • AQR Capital Management held 472,056 shares of Niagen Bioscience worth $1.51M as of Q2 2026.
  • AQR Capital Management sold 559,279 Niagen Bioscience shares in Q2 2026, an estimated $2.27M.
  • Niagen Bioscience made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2791 holding.
  • AQR Capital Management first reported a position in Niagen Bioscience in Q3 2019 and has held it in 18 quarters since.
  • AQR Capital Management's Niagen Bioscience position peaked at $7.08M in Q2 2025.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.